Cost-Effectiveness of Intravenous Ferric Carboxy Maltose Versus Iron Sucrose to Treat Anemia in Pregnancy in Indian Context
Author(s)
Beena N. Joshi, PhD, Other1, Tejal Varekar, MPH2, Revathy R, MPH3, Kiran Sangwan, MPH4, Deepti Tandon, MS1, Ragini Kulkarni, MD5, Shahina Begum, PhD1;
1National Institute for Research in Reproductive and Child Health, Scientist, Mumbai, India, 2National Institute for Research in Reproductive and Child Health, Health Economist, Mumbai, India, 3National Institute for Research in Reproductive and Child Health, Ex-Scientist, Mumbai, India, 4National Institute for Research in Reproductive and Child Health, Ex-Scientist, Mumabi, India, 5National Institute for Research in Reproductive and Child Health, Scientist, Mumabi, India
1National Institute for Research in Reproductive and Child Health, Scientist, Mumbai, India, 2National Institute for Research in Reproductive and Child Health, Health Economist, Mumbai, India, 3National Institute for Research in Reproductive and Child Health, Ex-Scientist, Mumbai, India, 4National Institute for Research in Reproductive and Child Health, Ex-Scientist, Mumabi, India, 5National Institute for Research in Reproductive and Child Health, Scientist, Mumabi, India
Presentation Documents
OBJECTIVES: To assess the cost-effectiveness of IV Ferric Carboxymaltose (FCM( vs IV Iron sucrose (ISC) to treat anemia in pregnancy in Indian context alongside a clinical effectiveness trial in public hospital settings
METHODS: A decision tree model was developed to estimate the cost and effect for moderate to severe anemic pregnant women for a time horizon from second trimester until 6 weeks post-partum. The analysis adopted an abridged societal perspective considering both the health system cost and the out-of-pocket expenditure. Incremental Cost utility analysis was undertaken along with Deterministic and probabilistic sensitivity analyses and budget impact for the IV FCM compared to the IV ISC.
RESULTS: The findings suggested that for a cohort of 2,100,214 pregnant anemic women in India needing parenteral iron treatment, the use of FCM as compared with ISC can result a total QALY gain of 2,36,904 years. The Incremental Cost Utility Ratio (ICUR) was estimated to be Rs 24,101 per QALY gained at 4 weeks post treatment and Rs. 23,290 per QALY gained at 6 weeks post-partum indicating that IV FCM is a cost-effective intervention at current price of Rs. 3030 for 1000 mg considering Threshold of one time GDP per capita for India. If IV FCM is purchased at Rs. 355 (171.60, 542.48) the intervention could be cost saving of approximately Rs. 560 crores as compared to the current market price for the cohort considered. Budget impact analysis revealed that for the management of Iron Deficiency Anaemia using IV FCM compared to the IV ISC for moderate to severe anemic pregnant women was estimated to incur an incremental cost of Rs. 596.57 crores for this cohort.
CONCLUSIONS: IV FCM is a costeffective intervention compared to IV Iron Sucrose to treat moderate to severe anemia in pregnancy at current price of Rs. 3030 per 1000 mg.
METHODS: A decision tree model was developed to estimate the cost and effect for moderate to severe anemic pregnant women for a time horizon from second trimester until 6 weeks post-partum. The analysis adopted an abridged societal perspective considering both the health system cost and the out-of-pocket expenditure. Incremental Cost utility analysis was undertaken along with Deterministic and probabilistic sensitivity analyses and budget impact for the IV FCM compared to the IV ISC.
RESULTS: The findings suggested that for a cohort of 2,100,214 pregnant anemic women in India needing parenteral iron treatment, the use of FCM as compared with ISC can result a total QALY gain of 2,36,904 years. The Incremental Cost Utility Ratio (ICUR) was estimated to be Rs 24,101 per QALY gained at 4 weeks post treatment and Rs. 23,290 per QALY gained at 6 weeks post-partum indicating that IV FCM is a cost-effective intervention at current price of Rs. 3030 for 1000 mg considering Threshold of one time GDP per capita for India. If IV FCM is purchased at Rs. 355 (171.60, 542.48) the intervention could be cost saving of approximately Rs. 560 crores as compared to the current market price for the cohort considered. Budget impact analysis revealed that for the management of Iron Deficiency Anaemia using IV FCM compared to the IV ISC for moderate to severe anemic pregnant women was estimated to incur an incremental cost of Rs. 596.57 crores for this cohort.
CONCLUSIONS: IV FCM is a costeffective intervention compared to IV Iron Sucrose to treat moderate to severe anemia in pregnancy at current price of Rs. 3030 per 1000 mg.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
HTA66
Topic
Health Technology Assessment
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, SDC: Reproductive & Sexual Health